Cardiovascular adverse events associated with norepinephrine–dopamine reuptake inhibitors: a pharmacovigilance study of the FDA Adverse Event Reporting System
Canadian Journal of Physiology and Pharmacology · 2024
DOI: 10.1139/cjpp-2024-0128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2024. Verfasst von Abhishek Kandukuru und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA, USA. Hauptthemen laut MEDLINE: Pharmacovigilance, Adverse Drug Reaction Reporting Systems, United States Food and Drug Administration, Cardiovascular Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Norepinephrine–dopamine reputake inhibitors (NDRIs), including bupropion, methylphenidate, atomoxetine, and reboxetine, are commonly prescribed for psychiatric disorders such as narcolepsy, attention-deficit/hyperactivity disorder, and depression. Cardiovascular adverse events have been reported to the FDA despite their effectiveness. This pharmacovigilance study analyzed cardiovascular adverse events associated with NDRIs using the FDA Adverse Event Reporting System data from January 2004 to December 2021. A retrospective analysis of adverse event reports was conducted, employing time-trend analysis and disproportionality evaluation to assess cardiovascular risks. Bupropion had the greatest reported odds ratios (RORs) for tachycardia (ROR = 4.2, 95% CI: 4.0–4.4) and hypertension (ROR = 3.5, 95% CI: 3.3–3.7), while methylphenidate showed greater ROR for arrhythmias (ROR = 2.8, 95% CI: 2.6–3.0) and palpitations (ROR = 3.1, 95% CI: 2.9–3.3). Reboxetine had signals for palpitations (ROR = 3.0, 95% CI: 2.8–3.2) and myocardial infarction (ROR = 2.7, 95% CI: 2.5–2.9), whereas atomoxetine revealed signals for hypertension (ROR = 2.9, 95% CI: 2.7–3.1) and syncope (ROR = 2.5, 95% CI: 2.3–2.7). Time-trend analysis revealed temporal variability in the cardiovascular risks connected with NDRIs. Our research elucidates cardiovascular safety profiles for NDRIs, highlighting the necessity for continuous pharmacovigilance. The observed variations in adverse events emphasize the need for ongoing surveillance to mitigate potential cardiovascular risks and enhance patient safety and treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA, USA.
ORCID-Profile: Vijaykumar Sutariya
Zitieren
APA
Kandukuru, A., Sharma, P., Verghese Gupta, S., Nkembo, A., & Sutariya, V. (2024). Cardiovascular adverse events associated with norepinephrine–dopamine reuptake inhibitors: a pharmacovigilance study of the FDA Adverse Event Reporting System. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2024-0128
Vancouver
Kandukuru A, Sharma P, Verghese Gupta S, Nkembo A, Sutariya V. Cardiovascular adverse events associated with norepinephrine–dopamine reuptake inhibitors: a pharmacovigilance study of the FDA Adverse Event Reporting System. Canadian Journal of Physiology and Pharmacology. 2024. doi:10.1139/cjpp-2024-0128
BibTeX
@article{Kandukuru2024,
author = {Kandukuru, Abhishek and Sharma, Priyanka and Verghese Gupta, Sheeba and Nkembo, Augustine and Sutariya, Vijaykumar},
title = {Cardiovascular adverse events associated with norepinephrine–dopamine reuptake inhibitors: a pharmacovigilance study of the FDA Adverse Event Reporting System},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2024},
doi = {10.1139/cjpp-2024-0128}
}
EUVIMED